Spatially Organized Dendritic Cell–t Cell Interactions Are Associated With Response to Cd40 Agonism in Non-muscle Invasive Bladder Cancer

Authors:
  • LBLucas Blanchard
    Lucas Blanchard
  • NYNing Yao
    Ning Yao
  • SASyed M. Alam
    Syed M. Alam
  • AGAli Ghasemzadeh
    Ali Ghasemzadeh
  • KWKarissa Whiting
    Karissa Whiting
  • VSVenkatraman E Seshan
    Venkatraman E Seshan
  • AMAndrew Mijacika
    Andrew Mijacika
  • CSCarlo Sevilla
    Carlo Sevilla
  • JAJuan Angulo-Lozano
    Juan Angulo-Lozano
  • VSVed P. Sharma
    Ved P. Sharma
  • MTMorgan Tomberlin
    Morgan Tomberlin

Abstract
CD40 agonism activates dendritic cells (DCs) and promotes T-cell antitumor immunity, but how tumor immune contexture shapes clinical responses remains unclear. We conducted a phase I study of intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), integrating spatial immune profiling. 2141-V11 was well tolerated, with no dose-limiting toxicities, and the recommended phase 2 dose was 70 mg. Clinical activity was observed, with 40% responses seen at any timepoint and durable benefit (median 20 months). Baseline tumors were immune-inflamed and enriched in tertiary lymphoid structures (TLS), whose abundance and maturity were not associated with response. Instead, response correlated with TLS composition, with enrichment of DC–CXCL13+ CD4+ and CD8+ T cell triads in responders, whereas non-responders showed increased DC-regulatory T cell proximity. These findings identify spatially organized DC–T cell interactions as a determinant of response to CD40 agonism in BCG-unresponsive NMIBC.